ArticleNature communications2023

Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha: a phase I trial.

James Spicer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.